Quality-of-Life Measurement in Blistering Diseases

Dermatologic Clinics

Volumn 30, Issue 2, 2012, Pages 301-307

  Sebaratnam, Deshan F ^a,b   Frew, John W ^a,b   Davatchi, Fereydoun ^c   Murrell, Dédée F ^b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autoimmune blistering disease; Bullous pemphigoid; Epidermolysis bullosa; Pemphigus; Quality of life; Vesiculobullous skin diseases

Indexed keywords

AUTOIMMUNE DISEASE; BLISTER; EPIDERMOLYSIS BULLOSA; GENETIC DISORDER; HUMAN; MORTALITY; PATIENT ATTITUDE; PEMPHIGUS; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; QUESTIONNAIRE; REVIEW; SHORT FORM 36; SYMPTOMATOLOGY; WELLBEING;

BLISTER; EPIDERMOLYSIS BULLOSA; FEMALE; HEALTH STATUS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84856305849     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.11.008     Document Type: Review

References (40)

1. WHOQOL Group The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995, 41:1403-1409.
2. World Health Organization. Constitution of the world health organization. In: Basic documents, 45th edition, Supplement, October 2006 from the Fifty-First World Health Assembly. Geneva (Switzerland): WHO; 2006. p. 1.
3. Chen S. Dermatology quality of life instruments: sorting out the quagmire. JInvest Dermatol 2007, 127:2726-2739.
4. Ware J., Sherbourne C. The MOS 36-item short form health survey (SF-36). Conceptual framework and item selection. Med Care 1992, 30:472-483.
5. Chren M.M., Lasek R.J., Floke S.A., et al. Improved discriminative and evaluative capability of a refine version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997, 133:1433-1440.
6. Both H., Essink-Bot M., Bussschbach J., et al. Critical review of generic and dermatology-specific health-related quality of life instruments. JInvest Dermatol 2010, 127:27726-27739.
7. Frew J.W., Murrell D.F. Quality of life measurements in epidermolysis bullosa: tools for clinical research and patient care. Dermatol Clin 2010, 28:185-190.
8. Sebaratnam D.F., McMillan J.R., Werth V.P., et al. Quality of life in patients with bullous dermatoses. Clin Dermatol 2012, 30:103-107.
9. Fine J.D., Eady R.A., Bauer E.A., et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. JAm Acad Dermatol 2008, 58:931-950.
10. Horn H.M., Tidman M.J. Quality of life in epidermolysis bullosa. Clin Exp Dermatol 2002, 27:707-710.
11. Finlay A., Khan G. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
12. Fine J.D., Johnson L.B., Weiner M., et al. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol 2004, 29:122-127.
13. Fine J.D., Johnson L.B., Weiner M., et al. Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size. Br J Dermatol 2005, 152:1009-1014.
14. Tabolli S., Sampogna F., Di Pietro C., et al. Quality of life in patients with epidermolysis bullosa. Br J Dermatol 2009, 161:869-877.
15. Goldberg D., Williams P. Auser's guide to the General Health Questionnaire 1988, NFER-Nelson, Windsor (United Kingdom).
16. Brooks R., Rabin R.E., de Charro F. The measurement and validation of health status using EQ-5D: a European perspective 2005, Kluwer Academic, Dordrecht (The Netherlands).
17. Ferrario S.R., Baiardi P., Zotti A.M. Update on family strain questionnaire: a tool for the general screening of caregiving-related problems. Qual Life Res 2004, 13:1425-1434.
18. Margari F., Leece P.A., Santamato W., et al. Psychiatric symptoms and quality of life in patients affected by epidermolysis bullosa. JClin Psychol Med Settings 2010, 17:333-339.
19. Frew J.W., Martin L.K., Nijsten T., et al. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol 2009, 161:1323-1330.
20. van Scheppingen C., Lettinga A.T., Duipmans J.C., et al. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol 2008, 88:143-150.
21. Dures E., Morris M., Gleeson K., et al. The psychosocial impact of epidermolysis bullosa. Qual Health Res 2011, 21:771-778.
22. Venugopal S.S., Yan W.F., Frew J.W., et al. First double-blind randomized clinical trial of intradermal allogeneic fibroblast therapy for severe generalized recessive dystrophic epidermolysis bullosa randomized against placebo injections resulted in similar wound healing that is independent of collagen VII expression. JInvest Dermatol 2010, 130:S67.
23. Frew J.W., Venugopal S.S., Murrell D.F. Quality of life outcomes of cultured allogeneic fibroblast therapy recipients with epidermolysis bullosa. Aust J Dermatol 2011, 52(Suppl 1):26.
24. Masahiro S., Shigaku I., Yutaka I., et al. An investigation of quality of life (QOL) of pemphigus patients in Japan (first report). JDermatol 2000, 110:283-288.
25. Terrab Z., Benchikhi H., Maaroufi A., et al. Quality of life and pemphigus. Ann Dermatol Venereol 2005, 132:321-328.
26. Mayrshofer F., Hertl M., Sinkgraven R. JDtsch Dermatol Ges 2005, 3:431-435. [in German].
27. Tabolli S., Mozzetta A., Antinone V., et al. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the Medical Outcomes Study 36-item short form health survey questionnaire. Br J Dermatol 2008, 158:1029-1034.
28. Krug S., Laughlin J. Handbook for the IPAT depression scale 1976, Institute for Personality and Ability Testing, Champaign (IL).
29. Krug S., Scheier I., Cattel R. Handbook for the IPAT anxiety scale 1976, Institute for Personality and Ability Testing, Champaign (IL).
30. Sampogna F., Tabolli S., Soderfeldt B., et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006, 154:844-849.
31. Paradisi A., Sampogna F., Di Pietro C., et al. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools. JAm Acad Dermatol 2009, 60:26-29.
32. Ikeda S., Imamura S., Hashimoto I., et al. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res 2003, 295(Suppl 1):S12-S16.
33. Sampogna F., Chren M., Melchi C., et al. Age, gender, quality of life and psychological distress in patients hospitalised with psoriasis. Br J Dermatol 2006, 154:325-331.
34. Pfütze M., Niedermeier A., Hertl M., et al. Introducing a novel Autoimmune Bullous Skin Disease Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 2007, 17:4-11.
35. Rosenbach M., Murrell D.F., Bystryn J.C., et al. Reliability and convergent validity of two outcome instruments in pemphigus. JInvest Dermatol 2009, 129:2404-2410.
36. Darjani A., Ghanbari A., Sayadi Nejhad A. Comparison of the health-related quality of life of patients suffering from pemphigus with healthy people. Journal of Guilan University of Medical Sciences 2008, 17:1-9.
37. Brorsson B., Ifyer J., Hays R.D. The Swedish Health-Related Quality of Life Survey. Qual Life Res 1993, 2:33-45.
38. Timóteo P., Simões Marques L., Bertoncello D. Rev Soc Bras Med Trop 2010, 43:580-583. [in Portuguese].
39. Hanna A., Sebaratnam D., Chee S., et al. Adisease-specific quality of life instrument for autoimmune bullous diseases-the ABQOL. Aust J Dermatol 2010, 52(Suppl 1):27.
40. Hanna A., Sebaratnam D., Chee S., et al. The development of a disease-specific quality of life instrument for autoimmune bullous dermatoses: the ABQOL. JInvest Dermatol 2011, 131(Suppl 2):S33.